Radiology department, Massachusetts General Hospital, Boston, MA, USA.
Br J Radiol. 2022 Jul 1;95(1135):20211225. doi: 10.1259/bjr.20211225. Epub 2022 May 5.
To analyse the frequency, demographics, primary disease and cumulative effective dose of patients undergoing two or more F-FDG PET/CT examinations in a year.
In a retrospective study performed at a tertiary-care hospital, patients who underwent ≥2 F-FDG PET/CT scans in a calendar year were identified for two consecutive years. The CT radiation dose was calculated using dose-length-product and sex-specific conversion factors. The primary malignancy of patients was retrieved from electronic medical records.
10,714 F-FDG PET/CT exams were performed for 6,831 unique patients in 2 years, yielding an average of 1.6 exams per patient. The maximum number of F-FDG PET/CT examinations any patient underwent in a single year was seven. 20.9% patients had ≥2 F-FDG PET/CT exams in any single year. Thirty nine percent patients in the cohort were below 60 years age. The median dose for F-FDG PET/CT examination was 25.1 mSv and maximum value reaching 1.7 to 2.9 times the median value. Cumulative effective dose (CED) was≥100 mSv in 12-13% of the patients. The cumulative dose for both years combined demonstrated the 25 percentile, 50 percentile and 75 percentile as well as the mean to be over 100 mSv, with the 25 percentile being 109 mSv. The dominant primary malignancies contributing to serial F-FDG PET/CTs in decreasing frequency were melanoma, non-Hodgkin's lymphoma (NHL), gastrointestinal cancer, breast cancer and Hodgkin's lymphoma.
A sizeable number of patients undergo≥2 F-FDG PET/CT exams with one out of every eight patients receiving cumulative dose≥100 mSv and that includes patients with long-life expectancy.
The study found that one of five patients had≥2 F-FDG PET/CT exams in a calendar year, one of four patients in two years and one of eight patients received cumulative dose≥100 mSv. Top malignancies associated with serial imaging in decreasing order of frequency included melanoma, non-Hodgkin's lymphoma (NHL), gastrointestinal cancer, breast cancer and Hodgkin's lymphoma.
分析一年内进行两次或以上 F-FDG PET/CT 检查的患者的频率、人口统计学特征、主要疾病和累积有效剂量。
在一家三级保健医院进行的回顾性研究中，连续两年确定了在日历年内进行了≥2 次 F-FDG PET/CT 扫描的患者。使用剂量长度乘积和性别特异性转换因子计算 CT 辐射剂量。从电子病历中检索患者的主要恶性肿瘤。
两年内共进行了 10714 次 F-FDG PET/CT 检查，涉及 6831 名患者，每位患者平均进行了 1.6 次检查。任何患者在单一年度内接受的 F-FDG PET/CT 检查次数最多为 7 次。20.9%的患者在任何一年中都进行了≥2 次 F-FDG PET/CT 检查。队列中有 39%的患者年龄在 60 岁以下。F-FDG PET/CT 检查的中位数剂量为 25.1 mSv，最大值达到中位数的 1.7 至 2.9 倍。12-13%的患者累积有效剂量（CED）≥100 mSv。两年累积剂量的 25 百分位数、50 百分位数和 75 百分位数以及平均值均超过 100 mSv，25 百分位数为 109 mSv。导致连续 F-FDG PET/CT 的主要恶性肿瘤依次为黑色素瘤、非霍奇金淋巴瘤（NHL）、胃肠道癌、乳腺癌和霍奇金淋巴瘤。
相当数量的患者进行了≥2 次 F-FDG PET/CT 检查，每 8 名患者中就有 1 名接受的累积剂量≥100 mSv，其中包括预期寿命较长的患者。
该研究发现，每 5 名患者中就有 1 名在一个日历年内进行了≥2 次 F-FDG PET/CT 检查，每 4 名患者中有 1 名在两年内进行了≥2 次检查，每 8 名患者中就有 1 名接受的累积剂量≥100 mSv。按频率降序排列，与连续成像相关的主要恶性肿瘤包括黑色素瘤、非霍奇金淋巴瘤（NHL）、胃肠道癌、乳腺癌和霍奇金淋巴瘤。
